59 results about "Stent restenosis" patented technology

A second stent having a wall thickness of 0.002 inches or less or a second stent having a tubular surface with openings therethrough where the ratio of the area of the surface to the area of the openings is at least 3:10 may be implanted in a first stent which has been previously implanted in a bodily vessel.

An expandable stent for implanting in a body lumen, such as a coronary artery, peripheral artery, or other body lumen includes cylindrical rings connected by undulating links. The stent has a high degree of flexibility in the longitudinal direction, yet has adequate vessel wall coverage and radial strength sufficient to hold open an artery or other body lumen. The distal and proximal end ring have peaks that extend longitudinally when the stent is radially expanded. The end ring extensions reduce the likelihood of the development of peri-stent restenosis.

Restenosis of arteries after angioplasty is inhibited by implanting in the treated artery a stent incorporating genes that encode gene products having anti-restenotic activity. The genes may be incorporated into a coating on the stent structure or in cells that are affixed to the stent. The genes or cells containing them may be adhered to the struts of the stent or incorporated in a collagen matrix that forms a coating covering the struts and interstices of the stent

This invention is directed to methods of preventing or treating diseases or conditions associated with excessive cell proliferation, remodeling, inflammation, and vasoconstriction. Particularly, this invention is directed to methods of treating cardiovascular diseases or conditions such as stent restenosis and thrombosis, vascular thrombosis, cerebral vasospasm, atherosclerosis, systemic hypertension, cardiac hypertrophy, and sexual dysfunction. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a novel Rho kinase inhibitor compound to treat the disease.

The invention discloses an iron-based composite material used for a full-degradation cardiovascular support and a preparation method thereof. The iron-based composite material comprises Fe and any one of W, Fe2O3, FeS and carbon nano tube, wherein the content of any one of W, Fe2O3, FeS and carbon nano tube is 0-10% and more than 0% in the iron-based composite material in percent by weight. The preparation method of the iron-based composite material comprises the following steps of: mixing iron powder with any one of tungsten powder, Fe2O3 powder, FeS powder and carbon nano tube powder, then carrying out spark plasma sintering or sintering by virtue of powder metallurgy, and cooling, so that the iron-based composite material is obtained. The iron-based composite material used for full-degradation cardiovascular support disclosed by the invention overcomes the defects of the traditional inert metal support such as late thrombosis and restenosis; and a secondary phase harmless to a human body is selected as a strengthening phase of the composite material, so that corrosion rate of an iron base in a body fluid environment is increased, and corrosion of the iron base is more uniform.

The present invention belongs to the field of biomedical engineering, in the concrete, it relates to a photosensitive scaffold with the function of preventing and curing restenosis. The photosensitizer can be used to modify the scaffold so as to obtain photosensitive scaffold, said photosensitive scaffold is placed in the pathological lumen, and irradiated by light, so that the photosensitizer on the scaffold can be activated so as to produce photochemical reaction to form active oxygen substance, resist endometrial hyperplasia / and prevent production of scaffold restricture.

The invention provides an intravascular stent covered by transgene cells, which is characterized in that: a low-temperature plasma treatment layer, an adhesive interstitial substance coat and a cell coat are orderly arranged on the surface of the naked metal stent. The adhesive interstitial substance coat is a protein coat or a peptide sequence coat; the cell coat is obtained by stabilizing transfected cells by target gene. Preparing the intravascular stent includes the following steps: obtaining the target gene; constructing and amplifying the eukaryotic expression carrier of the target gene; obtaining cells; modifying the surface of the metal stent; preparing the adhesive interstitial substance coat; rotating, cultivating, and preparing the intravascular stent covered by transgene cells. On the one hand, by expressing the target gene at high-level, the rehabilitating of the injured endovascular endoderm is enhanced and the multiplication of smooth muscle cells is inhibited; one the other hand, by the multiplication of external-source cells, the surface endothelialization of the intravascular stent is accelerated; the coating is close applied on the surface of the stent, the biocompatibility is fine, and the intravascular stent can be inhibited from turning narrower ultimately.

The invention discloses a drug balloon. The drug balloon comprises a balloon body and a drug coating located on the surface of the balloon body, wherein the drug coating comprises a drug and an excipient; the drug coating comprises a near-end coating, a middle-section coating and a far-end coating, the drug-loading density of one of the near-end coating and the far-end coating is larger than the drug-loading density of the middle-section coating, and the drug-loading density of the other one of the near-end coating and the far-end coating is not smaller than the drug-loading density of the middle-section coating. When stent restenosis lesions are treated, the drug balloon is selected to be pressurized according to lesion characteristics, the drug balloon has a supporting function, part ofthe coating with a large drug-loading density is close to severe stenosis lesions at the near end or the far end, the drug content is selectively increased, and the stenosis rate of severe lesion areais reduced; meanwhile, the total drug content of the whole lesions is reduced, and the drug toxicity and adverse reactions of the body are reduced.

The invention relates to an implanted completely bioresorbable blood vessel polymer support which comprises five or more annular wave-shaped supporting rods and connecting rods connected between the supporting rods at intervals. The supporting rods of the support are formed by alternately connecting quasi-arc-shaped waves and quasi-m-shaped waves, wherein the quasi-arc-shaped waves and the quasi-m-shaped waves are formed by connecting two sets of forward s and inverted s respectively, and every two adjacent supporting rods are connected by connecting the tops of the quasi-arc-shaped waves and the bottoms of the quasi-m-shaped waves through the corresponding connecting rod. The net pattern form of the polymer support is carved on a thin wall pipe through lasers. According to the scheme, the contradiction among the radial supporting force, the wall thickness and flexibility of the polymer support is resolved, the radial supporting force, the wall thickness and flexibility are considered at the same time, good passage capacity is achieved, enough mechanical supporting can be given to a lesion segment within the specific time of injury healing, the support is gradually absorbed by the body after injury healing, endothelialization is good, and the stenosis rate of the support and the risk of the support in later stent thrombosis are reduced effectively.

The invention relates to the field of coronary stents, specifically to a method for reducing the incidence of in-stent restenosis and its special stainless steel material. The method of the invention adds a proper amount of copper element (2.0-6.0% by weight) into the common clinical coronary stent material 316L stainless steel, and conducts special heat treatment so as to make the copper separated in a copper-rich phase out of the stainless steel substrate. The stent is enabled to continuously release trace amounts of copper ions in a clinical environment, and the coronary stent is endowed with an anti-restenotic function, thus effectively reducing the incidence of restenosis after stent implantation. With a unique function of reducing the in-stent restenosis phenomenon caused by stent implantation into a coronary artery, the 316L type copper-containing stainless steel of the invention is conducive to solve clinical problems such as high incidence of in-stent restenosis after implantation of existing stainless steel coronary stents, and can be applied in coronary stents and other clinical medicine fields, thus providing a new idea and material basis for development and application of coronary stents.

The invention discloses a traditional Chinese medicine preparation for curing angiocardiopathy stent restenosis and a preparation method thereof. The traditional Chinese medicine preparation comprises various components according to the parts by weight: 10-30 parts of dangseng, 10-30 parts of the root of red-rooted salvia, 10-30 parts of safflower, 10-30 parts of rhizoma cyperi, 10-30 parts of radix bupleuri, 10-30 parts of angelica, 10-30 parts of red paeonia, 10-30 parts of schisandra chinensis, 10-30 parts of pseudo-ginseng, 10-30 parts of asarum, 10-30 parts of heracleum hemsleyanum michaux, 10-30 parts of ophiopogon root, 10-30 parts of milk weteh, 10-30 parts of polygala tenuifolia, 10-30 parts of notopterygium root, 10-30 parts of spatholobus stem, 10-30 parts of rhizoma atractylodis, 10-30 parts of peach kernel, 5-10 parts of folium ginkgo, and 10-30 parts of the rhizome of chuanxiong. The traditional Chinese medicine preparation can effectively inhibit vascular smooth muscle of cell proliferation, platelet aggregation and thrombosis, reduces the issue rejection reaction and inhibits inflammatory reaction.

The present invention belongs to the field of biomedical engineering technology, in the concrete, it relates to a sound-sensitive scaffold with the function of preventing and curing restructure. It is characterized by that a sound-sensitive agent is used to modify the scaffold so as to obtain sound-sensitive scaffold. When it is used, the sound-sensitive scaffold is placed in the pathological lumen, and irradiated by ultrasonic wave for a proper time, so that the sound-sensitive agent on the scaffold can be activated so as to produced phonochemical reaction to form active oxygen substance, resist endometrial hyperplasia and prevent production of scaffold restructure.

The invention relates to the field of coronary stents, specifically to a method for reducing the incidence of in-stent restenosis and its special stainless steel material. The method of the invention adds a proper amount of copper element (2.0-6.0% by weight) into the common clinical coronary stent material 316L stainless steel, and conducts special heat treatment so as to make the copper separated in a copper-rich phase out of the stainless steel substrate. The stent is enabled to continuously release trace amounts of copper ions in a clinical environment, and the coronary stent is endowed with an anti-restenotic function, thus effectively reducing the incidence of restenosis after stent implantation. With a unique function of reducing the in-stent restenosis phenomenon caused by stent implantation into a coronary artery, the 316L type copper-containing stainless steel of the invention is conducive to solve clinical problems such as high incidence of in-stent restenosis after implantation of existing stainless steel coronary stents, and can be applied in coronary stents and other clinical medicine fields, thus providing a new idea and material basis for development and application of coronary stents.

The invention discloses a medicament for preventing in-stent restenosis after coronary stent implantation and a preparation method. The medicament is prepared into 1000 parts from, by weight, 800-1200 parts of tanshinone, 200-300 parts of hirudin, 20-30 parts of camphol and borneol and 6-9 parts of musk ketone. The medicament has the advantages of effective treatment, no toxic and side effects and capabilities of decreasing occurrence rate of in-stent restenosis after coronary stent implantation, obviously improving clinical symptoms of patients and reducing long-term risks of thrombosis of the patients, and is obvious in clinical effect. The medicament provides a new choice for preventing ISR (in-stent restenosis) after coronary stent implantation.

The invention discloses a blood contact type functional material as well as a preparation method and application thereof, and belongs to the field of medical instruments. The blood contact type functional material comprises a polyamine-phenol coating layer rich in amino groups and heparin functional molecules covalently grafted by utilizing the amino groups on the surface of the polyamine-phenol coating layer. It is found that when the functional coating layer is used as a surface coating layer of a blood contact implantation and interventional instrument, the functional coating layer can bear huge deformation caused by the device in the application process, and the problem that the functional molecules of heparin modified at the part are lost due to scratch and falling of the coating layer caused by friction is solved. The long-term antithrombotic function of the instrument is maintained in the application process due to the persistent high-activity retention and high-density grafting quality of the heparin on the surface of the instrument, surface endothelium regeneration of the interventional instrument such as a peripheral vascular stent can be promoted, and complications such as stent restenosis and advanced thrombosis are effectively inhibited.

The present invention relates to new use of inhibitors of bcl-2 / bcl-XI family of anti-apoptotic compounds for the treatment of post-angioplasty restenosis and in-stent restenosis. Small molecules of Bcl inhibitors are incorporated into a stent, typically by a fine polymeric coating over the metal, which would be placed during angioplasty of occluded blood vessels, to act on fibroproliferative in-growth. Hollow organs such as urethras, Fallopian tubes and vascular access grafts could be treated in a similar manner to prevent their closure due to fibrosis. Other iatrogenic fibrosis such as adhesions after surgery could also be blocked by this therapy.

A stent with multi drug-coatings includes a stent body and active drugs. A portion of the surface or the entire surface of the stent body is covered with at least one layer of active drug coating. Use of such a stent not only can accelerate endothelialization of coronary, but also resist cell proliferation, resist the migration of smooth muscle cells, reduce the formation of thrombus and the inflammatory reaction of cells and recover the flexibility of vascular tissues. Multi drug-coatings can prevent the multiple phases of restenosis, resist the release of drugs at different phases of endothelial repair, and play a role in co-resisting vessel stent restenosis by various drugs. Well-composed multi drug-coatings make the coating area and coating layers of drug-eluting stent and drugs compatibility more reasonable, make the use of drug-eluting stent more secure, and produce better treatment effects.

The invention discloses a composite drug intravascular stent which comprises a bare metal stent (prepared from a nickel-titanium memory alloy material), recombinant human collagen and folic acid are loaded on a stent body, HMGB1 fragment peptide and a VEGFR-2 antibody are crosslinked on the surface of the bare metal stent. Specifically, a dynamic liquid electrospinning technology is utilized to load a composite spinning solution of recombinant human collagen, folic acid, HMGBI fragment peptide and the VEGFR-2 antibody onto a nickel-titanium memory alloy bare metal stent to form an intravascular stent loaded with the recombinant human collagen and folic acid and cross-linked with the HMGBI fragment peptide and the VEGFR-2 antibody, so that EPCs capture, homing, proliferation and differentiation are promoted, and rapid endothelialization of the blood vessel is realized. The stent not only can be used for coronary stents, but also can be used for cerebrovascular stents, renal artery stents, main artery stents and the like.

A method of coating a surface of a stent with abcixmab (Reopro) which is one of glycoprotein IIb / IIIa receptor inhibitors is provided. In case of acute coronary occlusion, the stent made of a stainless steel treated with carbon is coated with the Reopro having an antiplatelet action against platelets, thereby remarkably preventing the stent restenosis. The coating method includes activating the surface through cleaning and plasma process, and coating the surface with a thin film having an amine radical. A process condition suitable for the feature of the carbon is induced at each process.

The invention discloses an iron-based material of surface patterning deposited metal and a preparation method and application of the iron-based material. The iron-based material of the surface patterning deposited precious metal comprises an iron-based basis material and the metal which is deposited on the surface of the iron-based basis material according to a pre-designed pattern; and the corrosion potential of the metal in simulated body fluid at the temperature of 35-40 DEG C is more positive than that of iron. According to the iron-based material, the metal element is used for forming patterned modification on the surface of the iron-based basis material, galvanic corrosion is formed between a pattern and a pure iron substrate, thus, corrosion of the iron-based basis material is further accelerated, and in addition, due to the designability of the material selection of the metal pattern, the pattern shape, the pattern distribution and the pattern number, comprehensive control of corrosion of the iron-based material is achieved. According to the iron-based material of the surface patterning deposited metal and the preparation method and application of the iron-based material, the iron-based material corrosion speed is controllable, the biocompatibility is good, the material can be used for manufacturing medical implants such as cardiovascular stents, and the problem that according to a traditional inert metal stent, late thrombosis, stent-restenosis and the like are caused is solved.

The invention provides a stent suitable for a urethral bent part. A body of the urethral stent is of a tubular structure made of a degradable or non-degradable material; the tubular structure is in astraight tube state before being implanted; at least one part of the tubular structure is bent after being implanted into a human body; the tube wall of the tubular structure is formed by arranging and combining concave hexagonal structures; and, in the concave hexagon at the bent position after being implanted into the human body, the included angle theta formed by the straight edges and the inclined edges of the concave hexagons sequentially arranged from the bent outer side to the bent inner side is gradually increased. After the urethral stent in the invention is implanted into a urethralstenosis part, both the inner diameter and the length of the stent can be increased by means of balloon dilatation and the like; furthermore, the stent can be bent at the same time after being implanted so as to adapt to physiological bending of a urethral membrane part, a ball part and a pubis anterior bending part; and thus, the problems of intimal hyperplasia, stent restenosis and the like caused by urethral straightening due to overlarge rigidity of the stent are solved.

The invention relates to an application of geraniin in stent coating medicines, and belongs to the technical field of biological medicines. By establishing an in-vitro vascular epidermal growth factor (EGF)-induced smooth muscle cell (VSMCs) proliferation model, the result proves that the geraniin can inhibit proliferation and migration of VSMCs and induce apoptosis of smooth muscle cells at the same time. In order to further verify the value of the geraniin in prevention of intra-stent restenosis (ISR) after percutaneous intracavitary coronary intervention (PCI), a preclinical pig coronary stent model is established, and research results prove that the geraniin coated stent can effectively inhibit pig coronary intimal hyperplasia and shows good histocompatibility and safety. The invention provides theoretical basis and experimental support for clinical application of the geraniin as a natural-source drug stent coating in prevention and treatment of PCI postoperative ISR.

The invention provides a medicine for preventing postoperative restenosis of coronary artery after percutaneous coronary intervention (PCI) and a preparation method, which pertain to the pharmacy field and are characterized in that: the medicine is prepared from the raw materials by decocting with water according to the following weight ratio: 25 to 35 of Chinese rhubarb: 10 to 20 of mirabilite: 10 to 20 of liquorice: 10 to 20 of cinnamon: 10 to 20 of peach kernel: 20 to 30 of leech: 15 to 25 of honeysuckle. The medicine of the invention solves the problems that the postoperative restenosis of coronary artery appearing in percutaneous coronary intervention (PCI) influences the curative effects and the conventional western medicines cause damage to liver function and renal function, massive hemorrhage, etc. when being used for preventing postoperative restenosis of coronary artery.

The invention discloses applications of sappan wood in the preparation of anti-PTCA postoperative restenosis and stent restenosis medicaments. Experimental research discovers that the sappan wood has obvious effects which are stronger than rapamycin in preventing and treating common carotid artery sacculus injured restenosis of bandicoots and iliac artery sacculus injured restenosis of rabbits, and can be prepared into anti-PTCA postoperative restenosis and stent restenosis medicaments so as to make the most of the whole adjusting advantages of multi-channel, multi-target and multi-link of the Chinese medicines and provide a high-effective, safe and economical solution for preventing and treating PTCA postoperative restenosis and stent restenosis.

The present invention relates to a pharmaceutical composition containing mesenchymal stem cells administered to a patient subjected to stenting. The present invention relates specifically to: a pharmaceutical composition for repairing and regenerating tissue, comprising mesenchymal stem cells, wherein the pharmaceutical composition is administered to a patient subjected to stenting; and the prevention of in-stent neointimal hyperplasia or in-stent restenosis with the pharmaceutical composition.